Attovia Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATTO Nasdaq 2836 www.attovia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Attovia Therapeutics, Inc.

Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says - Aug 31st, 2026 9:16 am
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls - Aug 31st, 2026 7:45 am
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More - Aug 31st, 2026 5:56 am
Moderna Stock Carries A Market Value Its Revenue Does Not Support - Aug 26th, 2026 9:13 am
Moderna Stock Had A Readout Waiting In Plain Sight - Aug 24th, 2026 1:01 pm
Moderna's Melanoma Result Landed On A Market Positioned The Other Way - Aug 20th, 2026 12:21 pm
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source - Aug 17th, 2026 7:10 am
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Aug 6th, 2026 2:05 pm
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq - Aug 6th, 2026 3:57 am
Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering - Aug 4th, 2026 6:50 pm